Success Metrics

Clinical Success Rate
87.5%

Based on 35 completed trials

Completion Rate
88%(35/40)
Active Trials
2(5%)
Results Posted
17%(6 trials)
Terminated
5(12%)

Phase Distribution

Ph phase_2
2
5%
Ph phase_3
21
50%
Ph phase_4
11
26%
Ph not_applicable
1
2%
Ph phase_1
4
10%

Phase Distribution

4

Early Stage

2

Mid Stage

32

Late Stage

Phase Distribution39 total trials
Phase 1Safety & dosage
4(10.3%)
Phase 2Efficacy & side effects
2(5.1%)
Phase 3Large-scale testing
21(53.8%)
Phase 4Post-market surveillance
11(28.2%)
N/ANon-phased studies
1(2.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

35 of 40 finished

Non-Completion Rate

12.5%

5 ended early

Currently Active

2

trials recruiting

Total Trials

42

all time

Status Distribution
Active(2)
Completed(35)
Terminated(5)

Detailed Status

Completed35
Terminated5
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
42
Active
2
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (10.3%)
Phase 22 (5.1%)
Phase 321 (53.8%)
Phase 411 (28.2%)
N/A1 (2.6%)

Trials by Status

terminated512%
recruiting25%
completed3583%

Recent Activity

Clinical Trials (42)

Showing 20 of 42 trialsScroll for more
NCT06619301Phase 3

RCT Glargine vs NPH for Treatment of DM in Pregnancy

Recruiting
NCT00383877Phase 3

Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed
NCT00504673Phase 3

Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes

Completed
NCT00313742Phase 4

The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins

Completed
NCT05124457Phase 2

DETERMINE: Detemir vs NPH

Recruiting
NCT00506662Phase 4

Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes

Terminated
NCT02131272Phase 3

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Terminated
NCT01486966Phase 4

Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes

Terminated
NCT00509925Phase 4

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

Terminated
NCT00435019Phase 3

Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Completed
NCT00725036Phase 3

Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes

Completed
NCT00605137Phase 3

Safety of Insulin Detemir in Children With Type 1 Diabetes

Completed
NCT00595374Phase 3

Efficacy and Safety of Insulin Detemir in Type 1 Diabetes

Completed
NCT00832182Phase 3

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

Completed
NCT00799448Phase 4

Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes

Terminated
NCT01562561Phase 3

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Completed
NCT00658099

Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®

Completed
NCT00104182Phase 3

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

Completed
NCT01486940Phase 3

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Completed
NCT00604344Phase 3

Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes

Completed

Drug Details

Intervention Type
DRUG
Total Trials
42